Tag - PRVL

Developments

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Prevail Therapeutics (NASDAQ:PRVL) dosed the first patient in its Phase 1/2 PROCLAIM trial evaluating PR006 for the treatment of frontotemporal dementia patients with GRN mutations. Frontotemporal dementia is the second...

December 11, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics’ (NASDAQ:PRVL) PR001 received FDA fast track designation for the treatment of neuronopathic Gaucher disease. Gaucher disease is a lysosomal storage disorder caused by mutations in the...

October 27, 2020

Developments

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

Prevail Therapeutics (NASDAQ:PRVL) received FDA fast track designation for PR006, a gene therapy candidate designed to slow the progression of frontotemporal dementia with a GRN mutation. Frontotemporal dementia is the...

March 24, 2020

Tag - PRVL

Prevail Therapeutics doses first patient in Phase 1/2 frontotemporal dementia trial

Prevail Therapeutics gets FDA fast track designation for Gaucher disease

Prevail Therapeutics gets FDA fast track designation for frontotemporal dementia gene therapy

General

More